Latest Commercial Readiness News

Viridis Mining has produced its first batch of high-grade Mixed Rare Earth Carbonate at its Poços de Caldas Demonstration Plant, advancing key milestones for the Colossus Project and setting the stage for commercial-scale rare earth production.

Mount Ridley Mines has launched its first major metallurgical testwork program at the Grass Patch Heavy Rare Earth Element Project, targeting processing pathways for its regolith-hosted rare earth, scandium, and gallium mineralisation.

Anson Resources' scoping study for its Green River Lithium Project in Utah reveals first quartile operating costs and a clear development pathway targeting 10,000 tonnes per annum lithium carbonate production by 2029.

Prairie Lithium has moved Pad #1 from groundwork to active building construction, backed by SaskPower's powerline installation and a binding Hydro Lithium offtake agreement that includes a A$10 million equipment contribution. First production is targeted for Q4 2026.

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.

Clean TeQ Water boosted its cash position and operational momentum in Q3 FY26, winning a A$10.4 million DESALX execution contract at Nyrstar Belgium, completing a uranium plant at Heathgate Resources, and advancing lithium and phosphate projects internationally.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Zeotech pushed forward its AusPozz™ metakaolin commercialisation with extended and new MOUs, progressed key Toondoon project approvals amid rising contractor costs, and launched live methane control trials.

GCM Corporation finalises exclusive rights to its Very High Density technology, launches its first commercial heat sink products, and expands global prototyping efforts targeting high-growth sectors including EV infrastructure and data centres.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Castile Resources has kicked off pilot plant bench scale testing for its Rover 1 project, integrating a 41% resource upgrade and higher metal prices into its Bankable Feasibility Study. The company also secured $8.4 million in funding and is preparing for exploration drilling amid regional consolidation.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.